Shares of CervoMed Inc. (NASDAQ:CRVO) jumped 30% on Monday following the release of new clinical data suggesting that its investigational therapy, neflamapimod, may significantly slow disease progression in patients with dementia with Lewy bodies (DLB).
The Boston-based biotech firm unveiled 32-week results from its RewinD-LB trial, indicating that patients who received neflamapimod experienced a 54% lower risk of clinically significant worsening compared to those on placebo, based on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale. For participants with minimal signs of concurrent Alzheimer’s Disease pathology, the benefit appeared even greater, with the risk reduction rising to 64%.
In addition to clinical outcomes, the treatment group also showed a notable decline in plasma levels of GFAP (glial fibrillary acidic protein)—a biological marker linked to neurodegenerative processes.
The findings were shared Sunday at the 2025 Alzheimer’s Association International Congress, with CervoMed emphasizing that no new safety concerns emerged during the study’s extension phase, and the treatment remained well tolerated.
“Reducing the risk of a 1.5-point worsening over 32 weeks on the CDR-SB by more than 50% would likely represent a clinically meaningful slowing of clinical progression at a level that patients and caregivers would notice in day-to-day function,”
— said Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center, who presented the results.
CervoMed also announced plans to meet with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to outline the design of its upcoming Phase 3 trial.
DLB is recognized as the second most common form of dementia, characterized by both cognitive and motor impairments, and remains an area with limited treatment options—heightening the significance of CervoMed’s latest results for patients and caregivers alike.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.